LAMEDITECH Co., Ltd.: debt-to-equity, ROE and more
KOSDAQ, Legal name LAMEDITECH Co., Ltd.
Latest figures are the FY2025 separate summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 199.3%
- Equity ratio
- 33.4%
- ROE
- -135.0%
- Op. margin
- -164.8%
- Rev. growth
- 9.3%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 2 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 separate | 34.3% | 74.5% | -28.3% | -182.8% | n/a |
| FY2022 separate | 43.7% | 69.6% | -64.2% | -160.6% | 99.7% |
| FY2024 separate | 16.7% | 85.7% | -49.5% | -146.9% | n/a |
| FY2025 separate | 199.3% | 33.4% | -135.0% | -164.8% | 9.3% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | ₩1.0B | ₩2.1B | ₩6.6B | ₩7.2B |
| Operating profit | -₩1.9B | -₩3.3B | -₩9.7B | -₩11.8B |
| Pre-tax income | -₩1.9B | -₩3.3B | -₩9.5B | -₩11.4B |
| Net income | -₩1.9B | -₩3.3B | -₩9.5B | -₩11.4B |
| Total assets | ₩8.9B | ₩7.5B | ₩22.3B | ₩25.2B |
| Total liabilities | ₩2.3B | ₩2.3B | ₩3.2B | ₩16.8B |
| Total equity | ₩6.6B | ₩5.2B | ₩19.2B | ₩8.4B |
| Paid-in capital | ₩643.0M | ₩664.0M | ₩4.3B | ₩4.4B |
| Debt/equity (source value) | 34.3% | 43.7% | 16.7% | 199.3% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 2012-01-13
- Listed
- 24/06/17
- Employees
- 68
- Auditor
- 태성회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1101114778316
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 라메디텍Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.